The content on this site is intended for healthcare professionals only
Prof Ali Bazarbachi speaks to ecancer about the real-world evidence on the use of antibody-drug conjugates in peripheral T-cell lymphoma.
Initially, he discusses the recent studies and the real-world evidence regarding the use of antibody-drug conjugates in peripheral T-cell lymphoma.
He further explains the results from ECHELON-2; 5-Year results of a randomised, double-blind, phase 3 study of frontline brentuximab vedotin + CHP VS CHOP in patients with CD30-positive peripheral T-cell lymphoma and what it means for the future of PTCL.
In the end, he mentions a few other studies presented in the last few years of significance regarding the use of ADCs for PTCL.
| 5-year results of ECHELON-2 study | |
| Real world evidence on the use of antibody drug conjugates in peripheral T-cell lymphoma | |
| Studies regarding the use of brentuximab vedotin for peripheral T-cell lymphoma |
This programme has been supported by an unrestricted educational grant from Takeda.
ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer
Multiple myeloma in a resource constrained setting
Synthetic biology and precision medicine in blood and gynaecological cancers
Multiple myeloma (A cancer arising from plasma cells)
OncoAlert Round Up for September 15-21, 2023
OncoAlert Round Up for August 25th - 31st, 2023
Choosing Wisely in radiology Tanzania
Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant tumours
